A detailed history of Vanguard Group Inc transactions in Kamada LTD stock. As of the latest transaction made, Vanguard Group Inc holds 1,384,430 shares of KMDA stock, worth $8.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,384,430
Previous 1,423,046 2.71%
Holding current value
$8.06 Million
Previous $7.06 Million 5.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$4.83 - $6.25 $186,515 - $241,350
-38,616 Reduced 2.71%
1,384,430 $7.43 Million
Q2 2024

Aug 13, 2024

BUY
$4.78 - $5.75 $468,535 - $563,615
98,020 Added 7.4%
1,423,046 $7.06 Million
Q1 2024

May 10, 2024

BUY
$5.58 - $6.42 $562,464 - $647,136
100,800 Added 8.23%
1,325,026 $7.43 Million
Q4 2023

Feb 14, 2024

BUY
$4.14 - $6.22 $838,590 - $1.26 Million
202,558 Added 19.83%
1,224,226 $7.49 Million
Q3 2023

Nov 14, 2023

BUY
$4.86 - $5.83 $71,077 - $85,263
14,625 Added 1.45%
1,021,668 $5.46 Million
Q2 2023

Aug 14, 2023

BUY
$4.48 - $5.53 $43,563 - $53,773
9,724 Added 0.98%
1,007,043 $5.32 Million
Q1 2023

May 15, 2023

BUY
$4.12 - $5.25 $14,300 - $18,222
3,471 Added 0.35%
997,319 $4.63 Million
Q4 2022

Feb 10, 2023

BUY
$3.79 - $4.84 $489,133 - $624,645
129,059 Added 14.92%
993,848 $3.99 Million
Q3 2022

Nov 14, 2022

BUY
$4.42 - $5.43 $259,476 - $318,768
58,705 Added 7.28%
864,789 $3.9 Million
Q2 2022

Aug 12, 2022

BUY
$4.22 - $5.85 $112,391 - $155,803
26,633 Added 3.42%
806,084 $3.64 Million
Q1 2022

May 13, 2022

BUY
$5.43 - $6.81 $129,060 - $161,860
23,768 Added 3.15%
779,451 $4.3 Million
Q4 2021

Feb 14, 2022

BUY
$5.21 - $6.82 $2,063 - $2,700
396 Added 0.05%
755,683 $4.97 Million
Q2 2021

Aug 13, 2021

BUY
$5.67 - $6.33 $4.28 Million - $4.78 Million
755,287 New
755,287 $4.4 Million

Others Institutions Holding KMDA

About KAMADA LTD


  • Ticker KMDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 44,800,500
  • Market Cap $261M
  • Description
  • Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...
More about KMDA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.